International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences
Vox Sanguinis · 2026-07 · 121 (7) · 1065-1075
DOI: 10.1111/vox.70269 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Vox Sanguinis, online erschienen am 20.04.2026. Verfasst von Arnaud Reggiani und 30 weiteren Autor:innen. Beteiligte Einrichtung: Bio-Rad Laboratories, DiaMed GmbH, Cressier, Switzerland. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Isoantibodies, Antibodies, Anti-Idiotypic, Erythrocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives Daratumumab, a therapeutic human anti‐CD38 monoclonal antibody, improves multiple myeloma outcomes but interferes with pre‐transfusion testing by binding CD38 on reagent red blood cells (RBCs), potentially masking clinically significant alloantibodies. This study aimed to evaluate the effectiveness of a novel high‐affinity anti‐idiotypic anti‐daratumumab reagent in neutralizing daratumumab interference while preserving RBC alloantibody detection and ensuring compatibility with routine transfusion laboratory workflows. Materials and Methods A non‐interventional, multicentre study across 28 transfusion laboratories in 15 countries evaluated a novel anti‐idiotypic anti‐daratumumab reagent (DaraClear). In total, 443 daratumumab‐containing plasma samples and 197 RBC alloantibody–containing samples were tested. All samples were initially tested at 10% (v/v), with stepwise escalation to 20% and 30% only if neutralization was incomplete. Neutralization efficiency, antibody detection, cross‐match resolution and workflow integration were assessed, alongside comparisons with dithiothreitol (DTT), papain, trypsin and DaraEx.
Results
Daratumumab interference was neutralized in 99.5% of samples, with 86.2% resolved using the 10% protocol. Detection of 190/197 RBC antibodies (96.4%) was preserved, including weak/low‐titre antibodies. Neutralization was superior to DTT (93.3%), papain/trypsin (84.9%) and DaraEx (68.4%; all p < 0.0001). Titration studies confirmed efficacy across various ranges of daratumumab titres. The reagent integrated seamlessly into workflows, remained stable over time and avoided RBC modification.
Conclusion
Daratumumab interference was efficiently neutralized while preserving alloantibody detection. The robust performance and workflow compatibility provide a practical solution for pre‐transfusion testing in daratumumab‐treated patients, supporting safe and timely transfusions with reduced laboratory burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bio-Rad Laboratories, DiaMed GmbH, Cressier, Switzerland.
- Interregional Blood Transfusion SRC Ltd., Bern, Switzerland.
- Laboratoire d'immuno-hématologie transfusionnelle, Hopitaux Universitaires de Genève, Genève, Switzerland.
- Blood Transfusion Service Zurich SRK, Schlieren, Switzerland.
- AOU Policlinico Umberto 1-Sapienza, UOC Immunoematologia e Medicina Trasfusionale, Rome, Italy.
- Azienda Ospedaliera San Camillo - Forlanini, UOC Medicina Trasfusionale e Cellule Staminali, Rome, Italy.
ORCID-Profile: Sofia Lejon Crottet, Jill R Storry, Carlos Cotorruelo
Zitieren
APA
Reggiani, A., Crottet, S. L., Waldvogel, S., Engström, C., Coluzzi, S., Matteocci, A., Hamilton, J. R., Kumas, L. T., de Vooght, K. M. K., Storry, J. R., Flores, J., Nogués, N., Cotorruelo, C., Rutherford, M., Nilsen, E. B., Pelc-Kłopotowska, M., Korzeniowska, J., Baffa, A., Sareneva, I., …, & Knappik, A. (2026). International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences. Vox Sanguinis, 121(7), 1065-1075. https://doi.org/10.1111/vox.70269
Vancouver
Reggiani A, Crottet SL, Waldvogel S, Engström C, Coluzzi S, Matteocci A, et al. International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences. Vox Sanguinis. 2026;121(7):1065-1075. doi:10.1111/vox.70269
BibTeX
@article{Reggiani2026,
author = {Reggiani, Arnaud and Crottet, Sofia Lejon and Waldvogel, Sophie and Engström, Charlotte and Coluzzi, Serelina and Matteocci, Antonella and Hamilton, Janis R and Kumas, Levent Tufan and de Vooght, Karen M K and Storry, Jill R and Flores, Jennylyn and Nogués, Núria and Cotorruelo, Carlos and Rutherford, Molly and Nilsen, Eveline B and Pelc-Kłopotowska, Monika and Korzeniowska, Jolanta and Baffa, Alessandra and Sareneva, Inna and Ahmad, Nor Hafizah and Szczudlo, Katarzyna and Rahman, Athif and Sanal, Laser and Jørgensen, Lise and Rochowiak, Karolina Majewska and Salwierz, Monika and Grancharova, Elisaveta and Zivkovic, Bojana and Alvarez, Jessica and Riedl, Mareike and Knappik, Achim},
title = {International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences},
journal = {Vox Sanguinis},
year = {2026},
volume = {121},
number = {7},
pages = {1065--1075},
doi = {10.1111/vox.70269}
}
EUVIMED